Berberine Attenuates Nonalcoholic Hepatic Steatosis by Regulating Lipid Droplet‐Associated Proteins: In Vivo, In Vitro and Molecular Evidence
Journal of Cellular and Molecular Medicine · 2025-04 · 29 (7)
DOI: 10.1111/jcmm.70524 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 07.04.2025. Verfasst von Hongzhan Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technol…. Hauptthemen laut MEDLINE: Berberine, Non-alcoholic Fatty Liver Disease, Lipid Droplets. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Hepatic lipid droplet (LD) accumulation is a hallmark of nonalcoholic fatty liver disease (NAFLD). Although the clinical efficacy of berberine (BBR) in treating NAFLD has been established, the mechanism remains uncertain. This study is to evaluate the effects of BBR on hepatic LDs and investigate the underlying mechanisms. Using high‐fat diet‐induced obese (DIO) mice as the model for NAFLD, BBR was administered daily by gavage for 4 weeks. Liver tissue was examined for changes in lipid deposition and histology. Transcriptomics was performed to screen differently expressed genes. The potential targets of BBR against NAFLD were then determined by Western Blot and immunostaining. In oleic acid (OA)‐induced HepG2 cells, the link between BBR and potential targets was further elucidated through the activation or antagonism of PPARα. The binding of BBR to potential targets was predicted using molecular docking. BBR significantly reduced hepatic steatosis by decreasing LD size rather than number. Transcriptomics with validation demonstrated that BBR modulated the expression of LD‐associated proteins CIDEA and PLIN4 in the liver. Further investigations revealed that BBR reversed the abnormal elevation of BSCL2 and PLIN2 in steatotic livers. Finally, we found that BBR reduced LD size in OA‐induced HepG2 cells by regulating BSCL2 and PPARα‐mediated CIDEA/PLIN4/PLIN2. Notably, BBR could bind well to PPARα and BSCL2. BBR can attenuate hepatic steatosis in DIO mice by reducing LD size through the regulation of LD‐associated proteins.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Rehabilitation Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
ORCID-Profile: Hongzhan Wang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, H., Wang, Z., Wang, D., Nie, K., Wu, W., Gao, Y., Chen, S., Jiang, X., Tang, Y., Su, H., Hu, M., Fang, K., & Dong, H. (2025). Berberine Attenuates Nonalcoholic Hepatic Steatosis by Regulating Lipid Droplet‐Associated Proteins: In Vivo, In Vitro and Molecular Evidence. Journal of Cellular and Molecular Medicine, 29(7). https://doi.org/10.1111/jcmm.70524
Vancouver
Wang H, Wang Z, Wang D, Nie K, Wu W, Gao Y, et al. Berberine Attenuates Nonalcoholic Hepatic Steatosis by Regulating Lipid Droplet‐Associated Proteins: In Vivo, In Vitro and Molecular Evidence. Journal of Cellular and Molecular Medicine. 2025;29(7). doi:10.1111/jcmm.70524
BibTeX
@article{Wang2025,
author = {Wang, Hongzhan and Wang, Zhi and Wang, Dingkun and Nie, Kexin and Wu, Wenbin and Gao, Yang and Chen, Shen and Jiang, Xinyue and Tang, Yueheng and Su, Hao and Hu, Meilin and Fang, Ke and Dong, Hui},
title = {Berberine Attenuates Nonalcoholic Hepatic Steatosis by Regulating Lipid Droplet‐Associated Proteins: In Vivo, In Vitro and Molecular Evidence},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
volume = {29},
number = {7},
doi = {10.1111/jcmm.70524}
}
EUVIMED